Evidence map›Paper›PMID 42039444›Full record

ArticlebioRxiv : the preprint server for biology2026

Heterogeneous, population-level drug-tolerant persisters exhibit ion-channel remodeling and ferroptosis susceptibility.

Corey E Hayford, Blake Baleami, Philip E Stauffer, B Bishal Paudel, Aziz Al'Khafaji, Amy Brock, Vito Quaranta, Darren R Tyson, Leonard A Harris

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Corey E HayfordChemical and Physical Biology Graduate Program, Vanderbilt University School of Medicine, Nashville, TN, USA.
Blake BaleamiHuman Genetics Graduate Program, Vanderbilt University School of Medicine, Nashville, TN, USA.
Philip E StaufferChemical and Physical Biology Graduate Program, Vanderbilt University School of Medicine, Nashville, TN, USA.
B Bishal PaudelChemical and Physical Biology Graduate Program, Vanderbilt University School of Medicine, Nashville, TN, USA.
Aziz Al'KhafajiCell and Molecular Biology Graduate Program, Integrated Life Sciences, University of Texas at Austin, TX, USA.
Amy BrockCell and Molecular Biology Graduate Program, Integrated Life Sciences, University of Texas at Austin, TX, USA.
Vito QuarantaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.
Darren R TysonDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Leonard A HarrisDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA.ORCID 0000-0003-2112-6940

Funding

Vanderbilt Biomedical Informatics Training ProgramT15LM007450 · NLM · VANDERBILT UNIVERSITY · PI Jessica S. Ancker, Bradley A. Malin · 2002 to 2026
$19.7M
TrainingU54CA113007 · NCI · VANDERBILT UNIVERSITY · PI QUARANTA, VITO · 2004 to 2014
$19.2M
Training in Fundamental NeuroscienceT32MH064913 · NIMH · VANDERBILT UNIVERSITY · PI IHRIE, REBECCA A, WINDER, DANNY G. · 2001 to 2022
$7.6M
Integrated Biological Systems Training in OncologyT32CA119925 · NCI · VANDERBILT UNIVERSITY · PI Vivian Gama, William Patrick Tansey · 2008 to 2026
$7.6M
Chemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0M
Instability of Cancer Cell States in Tumor progression (ICCS)R01CA255536 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI BROCK, AMY, HUANG, SUI · 2021 to 2025
$2.5M
Using label-free Raman microscopy to predict therapeutic resistance of TNBC cellsU01CA253540 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI BROCK, AMY, YANKEELOV, THOMAS E · 2020 to 2024
$2.1M
Research Specialist in Cancer Systems BiologyR50CA243783 · NCI · VANDERBILT UNIVERSITY · PI TYSON, DARREN R · 2019 to 2023
$781k
Uncovering the molecular networks underlying non-genetic heterogeneity in cancer cell populationsK22CA237857 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI HARRIS, LEONARD ALFREDO L. · 2020 to 2022
$563k
Uncovering the Molecular Basis of Phenotypic Diversification in BRAF-mutant MelanomaF31CA221147 · NCI · VANDERBILT UNIVERSITY · PI HAYFORD, COREY EDUARDO · 2017 to 2019
$134k
NCI NIH HHS F31 CA221147NCI NIH HHS K22 CA237857NCI NIH HHS R01 CA255536NCI NIH HHS R50 CA243783NCI NIH HHS T32 CA119925NCI NIH HHS U01 CA253540NCI NIH HHS U54 CA113007NIGMS NIH HHS T32 GM065086NIMH NIH HHS T32 MH064913NLM NIH HHS T15 LM007450
6 · The paper itself

Abstract

Drug-tolerant persisters (DTPs) represent a major obstacle to durable responses in targeted cancer therapy. DTPs are commonly described as distinct single-cell states that survive drug treatment via reversible, non-genetic mechanisms and drive tumor recurrence. Recent work demonstrates that multiple DTPs can coexist, reflecting diversity in lineage, signaling programs, or stress responses. However, each DTP is still generally viewed as a uniform cellular phenotype. Building on our prior work describing a population-level DTP termed "idling" [Paudel et al.,

Identifiers

PMID42039444
PMCPMC13105065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.